You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
SAVR 2.0 cm2
9.0 mm Hg
SAVR 11.7 mm Hg
As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1
EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2
1. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.
2. Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.
3. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. Published online September 18, 2018.
*Forrest J.K. M.D. On behalf of the Evolut Low Risk Investigators. The Evolut Low Risk Trial Complete 2-year follow-up. Presented at EuroPCR 2021.
SSAS = Symptomatic Severe Aortic Stenosis